U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06820281) titled 'Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes' on Feb. 06.
Brief Summary: This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 4 weeks of treatment with TZP. These measures will also be compared to a group of adults without diabetes (who will not receive treatment with TZP) to assess how met...